Curative resection after chemotherapy and chemoradiotherapy for postoperative recurrence of pancreatic tail cancer in the abdominal wall: a case report.
Abdominal wall recurrence
Femoral myocutaneous flap
Multidisciplinary therapy
Pancreatic ductal adenocarcinoma
Surgical margin
Journal
Surgical case reports
ISSN: 2198-7793
Titre abrégé: Surg Case Rep
Pays: Germany
ID NLM: 101662125
Informations de publication
Date de publication:
19 May 2022
19 May 2022
Historique:
received:
25
03
2022
accepted:
13
05
2022
entrez:
18
5
2022
pubmed:
19
5
2022
medline:
19
5
2022
Statut:
epublish
Résumé
Locoregional recurrence and metastasis to the liver, peritoneum, and lung are the most common recurrent patterns of pancreatic ductal adenocarcinoma (PDAC) after radical resection. Recurrence in the abdominal wall is extremely rare. Herein, we report our experience with a patient who had recurrent PDAC in the abdominal wall with long-term survival by means of multidisciplinary therapy. A 76-year-old Japanese woman was diagnosed with resectable pancreatic tail cancer. She underwent distal pancreatectomy with regional lymphadenectomy after two cycles of gemcitabine plus S-1 as neoadjuvant therapy. She also received eight cycles of S-1 as adjuvant chemotherapy. Approximately 14 months after the initial surgery, imaging examinations identified a mass suggesting recurrence in the abdominal wall at the middle wound that involved the transverse colon. After two cycles of gemcitabine plus nab-paclitaxel, chemoradiotherapy (S-1 plus 45 Gy) and seven cycles of modified FOLFIRINOX (5-fluorouracil/leucovorin, irinotecan, and oxaliplatin) were administered. The patient did not develop any new recurrent lesions during chemotherapy and chemoradiotherapy. Therefore, the recurrent lesion in the abdominal wall and the involved transverse colon were resected. We confirmed the lack of peritoneal dissemination during surgery. Pathological examination revealed that the resected lesion was metastasis of primary PDAC, and the surgical margin was 1 mm. However, re-recurrence localized in the abdominal wall was detected 9 months later. The re-recurrent lesion was diagnosed as local recurrence of the first recurrent lesion. We performed a second resection of the abdominal wall using a femoral myocutaneous flap to achieve sufficient surgical margin. The pathological findings of the resected specimen were the same as those of the previous specimens, and the resection margin was negative. The patient's postoperative course was uneventful. Seven years after the initial surgery and 3 years and 7 months after the third surgery, the patient is alive with no signs of recurrence. Long-term survival could be achieved by radical resection with sufficient surgical margins for recurrence of PDAC in the abdominal wall if new other recurrent lesions, including peritoneal dissemination, are prevented through chemotherapy.
Sections du résumé
BACKGROUND
BACKGROUND
Locoregional recurrence and metastasis to the liver, peritoneum, and lung are the most common recurrent patterns of pancreatic ductal adenocarcinoma (PDAC) after radical resection. Recurrence in the abdominal wall is extremely rare. Herein, we report our experience with a patient who had recurrent PDAC in the abdominal wall with long-term survival by means of multidisciplinary therapy.
CASE PRESENTATION
METHODS
A 76-year-old Japanese woman was diagnosed with resectable pancreatic tail cancer. She underwent distal pancreatectomy with regional lymphadenectomy after two cycles of gemcitabine plus S-1 as neoadjuvant therapy. She also received eight cycles of S-1 as adjuvant chemotherapy. Approximately 14 months after the initial surgery, imaging examinations identified a mass suggesting recurrence in the abdominal wall at the middle wound that involved the transverse colon. After two cycles of gemcitabine plus nab-paclitaxel, chemoradiotherapy (S-1 plus 45 Gy) and seven cycles of modified FOLFIRINOX (5-fluorouracil/leucovorin, irinotecan, and oxaliplatin) were administered. The patient did not develop any new recurrent lesions during chemotherapy and chemoradiotherapy. Therefore, the recurrent lesion in the abdominal wall and the involved transverse colon were resected. We confirmed the lack of peritoneal dissemination during surgery. Pathological examination revealed that the resected lesion was metastasis of primary PDAC, and the surgical margin was 1 mm. However, re-recurrence localized in the abdominal wall was detected 9 months later. The re-recurrent lesion was diagnosed as local recurrence of the first recurrent lesion. We performed a second resection of the abdominal wall using a femoral myocutaneous flap to achieve sufficient surgical margin. The pathological findings of the resected specimen were the same as those of the previous specimens, and the resection margin was negative. The patient's postoperative course was uneventful. Seven years after the initial surgery and 3 years and 7 months after the third surgery, the patient is alive with no signs of recurrence.
CONCLUSIONS
CONCLUSIONS
Long-term survival could be achieved by radical resection with sufficient surgical margins for recurrence of PDAC in the abdominal wall if new other recurrent lesions, including peritoneal dissemination, are prevented through chemotherapy.
Identifiants
pubmed: 35585274
doi: 10.1186/s40792-022-01452-3
pii: 10.1186/s40792-022-01452-3
pmc: PMC9117584
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101Subventions
Organisme : Japan Society for the Promotion of Science London
ID : JP21K16426
Informations de copyright
© 2022. The Author(s).
Références
JOP. 2012 May 10;13(3):296-300
pubmed: 22572136
Surg Case Rep. 2020 Jul 3;6(1):157
pubmed: 32621095
World J Gastroenterol. 2014 Jul 28;20(28):9354-60
pubmed: 25071330
Oncol Lett. 2016 Jun;11(6):3933-3938
pubmed: 27313720
BMC Cancer. 2019 May 17;19(1):468
pubmed: 31101022
J Gastrointest Surg. 2012 Sep;16(9):1696-704
pubmed: 22644446
Eur J Surg Oncol. 2009 Jun;35(6):600-4
pubmed: 19131205
Pancreas. 2012 Oct;41(7):985-92
pubmed: 22750974
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Surg Case Rep. 2019 Feb 13;5(1):21
pubmed: 30758733
Pancreatology. 2020 Jan;20(1):89-94
pubmed: 31787525
HPB Surg. 1990 Mar;2(1):51-4; discussion 54-5
pubmed: 2177999
J Gastrointest Surg. 2012 Dec;16(12):2294-6
pubmed: 23093448
HPB (Oxford). 2012 Jun;14(6):365-72
pubmed: 22568412
CA Cancer J Clin. 2020 Sep;70(5):375-403
pubmed: 32683683
Am J Surg. 2004 Jun;187(6):705-12
pubmed: 15191862